|Page (1) of 1 - 04/10/12||email article||print page|
Jury reaches verdict in Arkansas trial over Johnson & Johnson subsidiary's antipsychotics drug
LITTLE ROCK, Ark. (AP) ' Jurors have reached a verdict in Arkansas' billion-dollar lawsuit against a Johnson & Johnson subsidiary that makes the antipsychotic drug Risperdal.
Arkansas contends Janssen Pharmaceuticals Inc. downplayed and hid risks associated with Risperdal. Attorney Fletch Trammel says the company lied to doctors by saying the drug didn't cause weight gain, diabetes and other adverse side effects. The state wants a minimum of $1.2 billion in fines for the 250,000 prescriptions issued under its Medicaid program over a 3 -year period.
Janssen attorney James Simpson says the state failed to show the drug's labeling or packaging was misleading, deceptive or false.
The jury began deliberating Tuesday. The verdict was being announced Tuesday afternoon.
Janssen settled a similar lawsuit with Texas in January for $158 million, but did not admit liability or fault.